Trial Outcomes & Findings for Effect of Topical Application of Iodex® Balm on Local Surface Temperature (NCT NCT02424565)

NCT ID: NCT02424565

Last Updated: 2016-08-29

Results Overview

Local surface temperature was measured by the spectral order of colour after application of product. Infra-red camera was used to take 11 images with one just before application of product and remaining 10 images at every minute for first 10 minutes after application of product. IR camera converted the IR energy radiated by the body into electrical impulses, which were then digitally indicated on a spatial temperature map. IR camera represents the temperature distribution in a so-called rainbow or spectral order of colors. The predominant colour will be determined on a 5 point scale based on Thermal Images produced using Infra-Red Thermography (IRT) technique and recorded as either Blue, Green, Yellow, Orange or Deep Orange/Red (In increasing order of temperature). There was an approximate temperature difference of 0.5°C between adjacent colours on the map which was supposed to brought about by application of the product and considered significant.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

15 participants

Primary outcome timeframe

Every minute from baseline to 10 minutes

Results posted on

2016-08-29

Participant Flow

Participants were recruited at one center in India.

Of the 19 participants screened, 15 were randomized, 14 completed the study.

Participant milestones

Participant milestones
Measure
First Test Balm Then Placebo Balm
2 ± 0.2 g of test balm of 9g balm packed in each primary package was gently rubbed for 15 seconds on the affected knee joint, then a gap of 3 days as a washout period, followed by application of 2 ± 0.2 g of placebo balm of 9g balm packed in each primary package .
First Placebo Balm Then Test Balm
2 ± 0.2 g of placebo balm of 9g balm packed in each primary package was gently rubbed for 15 seconds on the affected knee joint, then a gap of 3 days as a washout period, followed by application of 2 ± 0.2 g of test balm of 9g balm packed in each primary package .
Period 1 (D0)
STARTED
8
7
Period 1 (D0)
COMPLETED
8
6
Period 1 (D0)
NOT COMPLETED
0
1
Washout Period
STARTED
8
6
Washout Period
COMPLETED
8
6
Washout Period
NOT COMPLETED
0
0
Period 2 (D3)
STARTED
8
6
Period 2 (D3)
COMPLETED
8
6
Period 2 (D3)
NOT COMPLETED
0
0

Reasons for withdrawal

Reasons for withdrawal
Measure
First Test Balm Then Placebo Balm
2 ± 0.2 g of test balm of 9g balm packed in each primary package was gently rubbed for 15 seconds on the affected knee joint, then a gap of 3 days as a washout period, followed by application of 2 ± 0.2 g of placebo balm of 9g balm packed in each primary package .
First Placebo Balm Then Test Balm
2 ± 0.2 g of placebo balm of 9g balm packed in each primary package was gently rubbed for 15 seconds on the affected knee joint, then a gap of 3 days as a washout period, followed by application of 2 ± 0.2 g of test balm of 9g balm packed in each primary package .
Period 1 (D0)
Protocol Violation
0
1

Baseline Characteristics

Effect of Topical Application of Iodex® Balm on Local Surface Temperature

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Overall Participants
n=14 Participants
Total number of participants randomized and treated in the study.
Age, Continuous
49.9 Years
STANDARD_DEVIATION 8.0 • n=39 Participants
Sex: Female, Male
Female
10 Participants
n=39 Participants
Sex: Female, Male
Male
4 Participants
n=39 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=39 Participants
Race (NIH/OMB)
Asian
14 Participants
n=39 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=39 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=39 Participants
Race (NIH/OMB)
White
0 Participants
n=39 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=39 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=39 Participants

PRIMARY outcome

Timeframe: Every minute from baseline to 10 minutes

Population: Intent-to-treat (ITT) population included all participants of safety population with any post-treatment assessment. Since no significant increase in surface temperature was observed in subjects for either treatment, therefore, number of subjects analyzed for this outcome is zero.

Local surface temperature was measured by the spectral order of colour after application of product. Infra-red camera was used to take 11 images with one just before application of product and remaining 10 images at every minute for first 10 minutes after application of product. IR camera converted the IR energy radiated by the body into electrical impulses, which were then digitally indicated on a spatial temperature map. IR camera represents the temperature distribution in a so-called rainbow or spectral order of colors. The predominant colour will be determined on a 5 point scale based on Thermal Images produced using Infra-Red Thermography (IRT) technique and recorded as either Blue, Green, Yellow, Orange or Deep Orange/Red (In increasing order of temperature). There was an approximate temperature difference of 0.5°C between adjacent colours on the map which was supposed to brought about by application of the product and considered significant.

Outcome measures

Outcome data not reported

Adverse Events

Test Balm

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Placebo Balm

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Results disclosure agreements

  • Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
  • Publication restrictions are in place

Restriction type: OTHER